GLOW is an assigned name for a specific mixture that consists of BPC-157 (10 mg), TB-500 (10 mg), and GHK-Cu (50 mg). GLOW is not a registered trademark, and each supplier may have a different formulation. Always read the label and check the exact composition. The version of the GLOW mixture discussed in this article is 10/10/50.
BPC-157 is a 15-amino-acid-peptide made from a protein present in gastric juice. Using rats, scientists found that the peptide is effective in tendon healing, digestion, and blood vessel formation. TB-500 is a part of Thymosin Beta-4, a protein that helps in the regulation of actin and in the healing process. GHK-Cu is a tripeptide with an ability to bind to copper and is widely studied for skin treatment.
50 mg of GHK-Cu predominates in the vial due to its high mass; hence the color of the reconstituted solution is visibly blue. The blue is not an indication of contamination but rather of a copper complex. Researchers have contacted us repeatedly showing concerns regarding the color, and the answer has not changed; when the mixture is colorless, then the quality of GHK-Cu is questionable.
GHK-Cu attaches itself to only one copper ion, which is taken as a signaling key deep down into gene expression. A paper published in 2018 discovered that GHK-Cu helps to trigger the processes of collagen, elastin, glycosaminoglycans synthesis, and tissue damage repair. And that is the number of genes - close to 4,000 - the reason why experts continue investigating this particular compound.
The level of GHK in plasma is variable depending on the individual’s age. Someone aged 20 has a plasma concentration of GHK of 200 ng/mL at most, but the level drops to close to 80 ng/mL at the age of 60. The decline in GHK levels can be related to slower wound healing, thinner skin, and less collagen turnover; however, any correlation rather than causation and neither of the clinical studies conducted globally aimed at restoring GHG levels to those corresponding for youth of tissues.
The copper ion is not in itself a decorative substance. GHK without copper exhibits decreased activity in most assays. It is the complexation that makes this compound capable of passing through the cell membranes and activating superoxide dismutase and other copper-dependent enzymes.
The most compelling evidence for the human efficacy of GHK-Cu is found in the field of topical skin products. Controlled clinical studies indicate that GHK-Cu formulations do indeed help tighten the skin, increase elasticity and firmness, and minimize wrinkles, photodamage, and hyperpigmentation when compared to vehicle controls. These are studies that have formal measurable endpoints and are not anecdotal.
Data on wound healing stems from animal studies and laboratory work. In these tests, GHK-Cu promoted re-epithelialization, increased fibroblast movements and reduced the amount of inflammatory cytokines released. Whether these results can be reproduced in humans is currently being researched - see the information on the FDA status below in relation to the ongoing Phase 2 clinical trial.
People often search for information related to acne and sagging skin. One way in which these problems may be linked is the anti-inflammatory and collagen-stimulating nature of GHK-Cu. However, there haven't been any human clinical trials where patients were treated for acne and the effect on skin laxity was examined.
Research on hair follicles has revealed that GHK-Cu increases the size of hair follicles and activates keratinocytes in experimental animals (rodents) and in vitro. In addition, GHK-Cu inhibits 5-alpha reductase enzyme in cells, which is the same enzyme inhibited by finasteride. Although the pathways overlap, GHK-Cu should not be considered as an alternative to finasteride practice wise as there has been no head-to-head human trial conducted.
What Research Does Not Prove: That subcutaneous administration of GHK-Cu helps in reaching hair follicle area in appreciable amounts, that humans possess any dose-response relationship, or that hair number increases during randomized trial. The follicular data is new and mainly animal data. We present it here because this question is the most popular one we got regarding this ingredient and getting an honest answer is more important than getting a false reassurance.
The timelines presented below illustrate the results obtained from research on topical GHK-Cu in human skin as well as on small mammals regarding hair. These timelines cannot be considered future forecasts for particular people either.
Weeks 1-2: Skin changes not visible yet. The collagen building process works slowly on the skin structure.
During weeks 4-6 of the human topical research, participants start showing improvements in their skin firmness and fine lines. This is the earliest time when controlled data becomes available in the study.
Weeks 8 through 12: In the studies conducted, there has been noticeably positive progress in the areas of elasticity and signs of photodamage during the timeline from weeks 8 to 12, as per published scientific articles.
Period 3 to 6 months (hair): Studies of rodent follicles make use of observation intervals of three to six months. The biology of the human hair cycle implies that changes in structure will become visible only after a long time interval.
According to what has been published, no differences in dosage have been found between men and women. Hormonal changes in the body influence hair loss causes, but they have no effect on the way GHK-Cu acts at the receptor level based on the current information.
The topical form of GHK-Cu has been used in humans while the injectable form of GHK-Cu has not. All of the controlled studies reporting positive skin results have been performed using topical gels or sprays that are applied directly to the problem area. Studies on the injectable form of GHK-Cu have been conducted with respect to systemic effects, but there are no comparable human studies which suggest effectiveness on the skin with that form.
| Feature | Topical (Cream / Serum) | Injectable (Subcutaneous) | Nasal Spray |
|---|---|---|---|
| Human Skin RCT Data | Yes - multiple controlled trials. | No. | No. |
| Penetration Barrier | Stratum corneum limits depth. | Bypasses skin barrier. | Mucosal absorption. |
| Systemic Distribution | Minimal. | Yes. | Partial. |
| Stinging at Application | Rare, mild. | Common (GHK-Cu copper complex). | Possible nasal irritation. |
| Regulatory Status | Cosmetic ingredient (Copper Tripeptide-1). | Research use only. | Research use only. |
| Available from US Peptide Labs | Via KLOW blend or singles. | Via KLOW blend or singles. | GHK-Cu Nasal Spray $110. |
<p style="font-family: 'Arial', sans-serif; font-size: 14px; color: #1a1a1a; margin: 20px 0; line-height: 1.6;">
Study protocols pick the <span style="color: #1a1a1a; font-weight: 600;">injectable route</span> when the goal is systemic distribution rather than targeted delivery into skin tissue. When the research question goes back to skin changes themselves, topical is the route backed by actual human data.
</p>
The chart will only provide reference and other information for research purposes. The GLOW formulation ratio involves the following combinations (10 mg BPC-157, 10 mg TB-500, 50 mg GHK-Cu in a 70 mg bottle) being mixed, forming a final concentration of 35 mg/mL after dissolving it in a 2 mL bacteriostatic water. All calculations used in this chart come from this agreed-upon ratio. To find out more about glow peptide dosage chart and protocol reference, visit Get US Peptides website.
| Research Dose | Volume (2 mL Recon) | BPC-157 Per Dose | TB-500 Per Dose | GHK-Cu Per Dose |
|---|---|---|---|---|
| 10 units (0.1 mL) | 0.1 mL. | 71 mcg. | 71 mcg. | 357 mcg. |
| 15 units (0.15 mL) | 0.15 mL. | 107 mcg. | 107 mcg. | 536 mcg. |
| 20 units (0.2 mL) | 0.2 mL. | 143 mcg. | 143 mcg. | 714 mcg. |
The GHK-Cu dose for every injection is five times more than that of BPC-157 and TB-500 as the content of the vial is 71% by mass. Moreover, studies stating that the daily use is 10-20 units are talking about the total blend and not about the single products.
Published protocols suggest the use of 2-3 mL of bacteriostatic water for the 70 mg GLOW vial. The total concentration is 35 mg/mL with 2 mL of bacteriostatic water, and 23.3 mg/mL with 3 mL of bacteriostatic water. The lower concentration of bacteriostatic water minimizes the stinging sensation of GHK-Cu at the injection site, which is the primary reason many researchers favor such a high dilution. Please recheck the calculation of units to milligrams using the Get US Peptides peptide dosage calculator before proceeding with any reconstitution.
Most frequently, research protocols regarding the GLOW blend have been based on either daily subcutaneous injection or a 5 days on/2 days off procedure for six to eight weeks. No studies support the preference for morning administration of any of the ingredients over evening. Use of time in protocols is generally determined based on the consideration of convenience rather than its circadian significance.
The literature does not suggest any differences in doses based on gender for any of the three components. The same dose is used in the study for both men and women.
GLOW blend research protocols utilize the subcutaneous injection method to deliver the product into the necessary sites, usually under the skin of the abdomen or outside thighs where there is sufficient amount of fat tissue to absorb the compound comfortably. In some research protocols involving the use of BPC-157 on rodents, intramuscular injection is utilized although this is not the recommended way of applying GLOW blend on humans.
GHK-Cu is the agent that causes the burning sensation at the injection site. The acidity of the copper complex is slight, and the copper ion can also irritate the tissue at elevated concentrations. According to the documented solution in protocols, this problem is resolved simply by dilution, since using 3 mL of bacteriostatic water instead of 2 mL decreases the concentration of copper by one-third of volume, which most researchers state significantly helps to diminish burning sensations.
According to the protocols, it is advisable to warm the reconstituted solution to room temperature, by removing it from the refrigerator for about 10-15 minutes before the injection process. However, this is a general recommendation that applies to any peptide solution, rather than being specific to GHK-Cu.
According to the findings of research and community involvement, the commonest side effect is a stinging sensation at the site of administration, accompanied by temporary redness which has been attributed to GHK-Cu as explained earlier. This is a normal phenomenon and ends within a few minutes to one hour.
The phrase “copper uglies” is used in certain peptide circles to describe a transient situation in which people suffer from skin problems, excess oiliness, or mild inflammation during the first 1-2 weeks of GHK-Cu administration. The rationale behind it is that the skin is undergoing accelerated turnover, akin to the first stages of retinoid purging. However, this effect has not been researched in a controlled manner, and is only based on community observations.
High dosages tend to raise an issue when it comes to copper load. The use of GHK-Cu in the field of research has yielded low-dose copper (micrograms) dosage levels that are far below the highest acceptable intake level of copper in food (10 mg/day for adults) but pharmacokinetics of injected copper compounds differs from those of dietary copper and has not yet been studied extensively in research on human subjects.
GHK-Cu should not be utilized by two categories of people based on their existing knowledge of copper metabolism pathology. Wilson's disease is described as a genetic condition that impairs the body's ability to excrete copper - the induction of copper overload is not advised. Pregnancy is a categorical exclusion for all components of the GLOW combination due to the lack of safety data in this population.
BPC-157, which represents the main obstacle to GLOW formulation, was included in the FDA's Category 2 bulk drug substances list published in September 2023. The FDA's Category 2 framework highlights the preparations having important safety issues, such as those related to immunogenicity and impurities, making compounding impossible as per regulations 503A and 503B. Being listed as Category 2 BPC-157 prohibits any licensed compounding pharmacy from making GLOW formulation for use by patients.
A study is being conducted comparing the topical GHK-Cu gel against a control formulation for wound healing and scar quality. The fact that this GHK-Cu trial exists confirms two things: firstly, the need for more human studies with GHK-Cu; and secondly, the lengthy FDA route required for gaining approval for a GHK-Cu drug.
GHK-Cu falls under two distinct legal terms. One of them is Copper Tripeptide-1 in a serum or cream for cosmetic purposes, which is permitted for buying and trading in the US. The second category is injectable peptide for research purposes in a laboratory as a research chemical, not for humans – this refers to the case that applies to GLOW.
The FDA's July 2026 Pharmacy Compounding Advisory Committee meeting evaluated BPC-157, TB-500, and KPV with respect to their eligibility for inclusion on the 503A Bulks List. At the time of the meeting, none of the components in the GLOW or KLOW blends were approved for compounding; their regulatory status is still pending the FDA taking any further actions.
GHK-Cu is not listed among WADA's prohibited substances while the situation is drastically different for the drug TB-500. TB-500 is just a fragment of the Thymosin-Beta-4 compound, which makes any combination containing this ingredient as banned for WADA-tested athletes irrespective of its purpose. WADA regulations have no therapeutic use exemptions in case of TB-500.
In the context of cosmetic research studies, combined use of topical GHK-Cu with microneedling is an established practice because the latter technique ensures creation of temporary microchannels which allow the active ingredients applied topically to penetrate into the skin. Nonetheless, although this combination has been discussed in dermatology literature, the number of controlled trials directly evaluating GHK-Cu together with microneedling versus microneedling is limited.
Retinol and GHK-Cu work on similar pathways as both of these substances result in enhanced collagen production; however, they differ in their processes (the production due to retinol occurs via RAR nuclear receptors while GHK-Cu activates gene expression using copper). The two substances are considered compatible in topical applications. One thing to note is that GHK-Cu produces stable effects in lightly acidic conditions and highly acidic conditions of vitamin C (i.e. L-ascorbic acid with a pH lower than 3.5) can destabilize the copper compound if mixed in one step. Sequential application is the most recommended procedure.
For protocols that combine peptides, including the GLOW combination with other peptides used in research, relevant literature can be found in combination protocols reference page on Get US Peptides and beauty protocols page.peptides for skin guide covers more general classification.
AHK-Cu (copper peptide of alanine-histidine-lysine) is a copper peptide similar to GHK-Cu, though sometimes advertised as a version for hair application. Whereas both copper peptides act similarly in their copper-chelation mode of action, they differ in their tissue-binding properties, with AHK-Cu preferring hair and scalp tissues, whereas the GHK-Cu is associated with wider gene expression profile and has more dermatological studies. Neither undergoes RCT clinical studies. AHK-Cu is not an ingredient in GLOW or KLOW.
| Stack / Compound | Components | Primary Research Angle | GHK-Cu Included | KPV Included | WADA Concern |
|---|---|---|---|---|---|
| GHK-Cu Alone | GHK-Cu only. | Skin, collagen, wound healing. | Yes. | No. | No. |
| GLOW Blend | BPC-157 + TB-500 + GHK-Cu. | Recovery + skin/collagen. | Yes. | No. | Yes (TB-500). |
| KLOW Blend | BPC-157 + TB-500 + GHK-Cu + KPV. | Recovery + skin + gut inflammation. | Yes. | Yes. | Yes (TB-500). |
| Wolverine Stack | BPC-157 + TB-500. | Tendon, gut, systemic recovery. | No. | No. | Yes (TB-500). |
| AHK-Cu | AHK-Cu only. | Follicle / hair (preliminary). | No. | No. | No. |
<p style="font-family: 'Arial', sans-serif; font-size: 14px; color: #1a1a1a; margin: 20px 0; line-height: 1.6;">
GLOW and KLOW differ on one peptide: <span style="color: #1a1a1a; font-weight: 600;">KPV</span>. KPV is derived from alpha-MSH and has shown gastrointestinal modulation in mouse and in vitro studies. For research on gut inflammation, inflammatory bowel disease models or anti-inflammatory work in general, KLOW is the fit. For protocols narrowly focused on recovery plus skin and collagen, GLOW is the match. Since the store does not carry the GLOW SKU, KLOW is the route when GLOW-style components are needed alongside KPV.
GLOW and Wolverine differ on one component: GHK-Cu. The <a href="https://getuspeptides.com/peptide-library/wolverine/" style="color: #1a1a1a; font-weight: 500;">Wolverine stack</a> (BPC-157 + TB-500) fits tendon, gut and systemic recovery when skin or collagen endpoints are not needed. Adding GHK-Cu shifts the research focus toward skin and collagen recovery.
</p>
The GLOW (BPC-157 / TB-500 / GHK-Cu) SKU is not available from US Peptide Labs at this time, but there are different possible ways to acquire the information from their store.
KLOW blend is available in KLOW at $145.00, which includes all three components of GLOW plus KPV in a single 10 mL vial. Pricing for multiple orders becomes $137.75 each for two or more vials and $130.50 each for five vials or more. Orders worth $70 or above get free shipping in the US. Generally, this is the preferable option for most researchers as it involves a single reconstitution, single lot number, and single COA.
Choice 2 - Assemble your GLOW according to your specifications: Merge BPC-157 / TB-500 Wolverine Stack at $85.00 and GHK-Cu at $60.00 for just $145.00 - the same cost of KLOW but you receive two vials and two different preparation methods. Choose this option if you prefer to tailor the GHK-Cu dosage as separate from that of the BPC-157/TB-500 treatment.
The most basic quality indicator of GHK-Cu relates to its blue-colored nature whereby a proper formulation will show a change in color after reconstitution. The appearance of a colorless solution after adding bacteriostatic water will signal the failure or degradation of the copper peptide in the vial representing GHK-Cu.
The term "99% purity" in a peptide Certificate of Analysis (COA) indicates that HPLC purity is being referred to, which is based on the total amount of UV-absorbing substance at target retention time. It does not suggest the peptide's percentage in the vial contents by mass, since excipients and water of crystallization are omitted from the measurement. Lot-specific independent-lab COAs are available from US Peptide Labs upon request, with the lot number indicated at the bottom of the vial. The COA reading guide on Get US Peptides has more information on how to read these documents. Furthermore, lab reports can also be obtained at the US Peptide Labs quality COAs page.
Every peptide available from US Peptide Labs is produced in US laboratories, sold only for laboratory research purposes, and requires buyers to be at least 21 years old. The healing and recovery collection provides a complete list of complementary research peptides.
Based on the studies, GHK-Cu has been examined for its effects on collagen synthesis, skin structure, wound healing, and hair follicle activity. The best researched area of its application in humans is topical skin use. Randomized studies have demonstrated the effectiveness of GHK-Cu in improving skin elasticity, fine lines, and photodamage. As an injectable experimental peptide, GHK-Cu is also used to check systemic effects, but information on human injections remains limited compared to topical studies.
This website is meant strictly for research purposes and does not offer personal information on dosing. The recommended dosage for the GLOW blend is 10-20 units daily, subcutaneously according to the 2 mL of 70 mg vial reconstitution; amounting to 357-714 mcg per dose. Please refer to GLOW dosage reference page for the full unit-to-milligram calculations.
In a research setting, a 50 mg of GHK-Cu will need 1-2 mL of bacteriostatic water for mixing which brings about a concentration of around 25-50 mg/mL. As for the 70 mg GLOW blend vial, the water volume used varies between 2-3 mL. You will need to use more water to reduce the concentration per dosage and lessen the pain from the injection. You may refer to peptide dosage calculator for the concentration calculations.
Research conducted on rodents and in vitro indicates that GHK-Cu increases hair follicle size and activates follicle keratinocytes. GHK-Cu is also able to inhibit 5-alpha reductase in cell culture. However, no clinical trial involving human subjects has proved that GHK-Cu increases hair count in either topical or injectable form. Although the findings on follicles offer hope, they are still in their infancy, and the process of administration through injections must be further investigated before its ability to release significant amounts of the substance into the hair follicles is established.
In regard to skin effects, topical GHK-Cu has shown to be more effective in humans than the injectable form. Controlled topical studies measured the improvements in the condition of the skin. While injectable GHK-Cu is used in excessive amounts, it doesn't have the same amount of evidence from the trials. The two types cannot be compared directly since they are studied for different purposes.
GHK-Cu has not been approved by the FDA in any form as a medication. It is legal to use GHK-Cu as an ingredient in cosmetics under its name of Copper Tripeptide-1 in the U.S. GHK-Cu as an injectable research peptide is sold lawfully for research purposes only. BPC-157, which is a component of the GLOW blend, is classified as a bulk drug substance, thus the GLOW blend is not allowed to be prepared by any 503A pharmacy. GHK-Cu itself is not on the list of prohibited substances by WADA, but the other ingredient TB-500 in the GLOW blend is termed a prohibited substance under the WADA rules applicable in 2026.
View KLOW (GLOW + KPV) at US Peptide Labs - $145.00, lot-specific COA, free US shipping from $70